Safety and efficacy of commonly used antimicrobial agents in the treatment of enterococcal infections: a review

ABSTRACT Introduction: Enterococci have become the second leading cause of nosocomial infections in the U.S, which are associated with higher morbidity, mortality, length of stay, and cost due to escalating resistance to several antimicrobial agents. With limited treatment options, the adverse events associated with the increasing use of available agents must be considered. Areas covered: Safety data about the most commonly used antimicrobial agents to treat enterococcal infections (ampicillin, vancomycin, linezolid, daptomycin, and tigecycline) derived from animal models, clinical trials and post-marketing surveillance are evaluated. However, most of these agents are not FDA approved and have been used for off-label indications in enterococcal infections. Expert opinion: The commonly used antimicrobials to treat enterococcal infections have unique safety profiles and side effects but are generally safe and tolerated in the short-term based on data from clinical trials and post-marketing surveillance. However, serious long-term adverse events may occur, and antibiotic selection should be individualized and based on source of infection, duration, potential drug-related toxicity, and drug-drug interactions to minimize side-effects. Implementing standard precautions and infection control measures, minimizing unnecessary antibiotic exposure, and optimizing treatment and duration with removal of source of infection are essential to prevent the spread of resistance and improve outcomes.

[1]  Tsutomu Kobayashi,et al.  Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction , 2011, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[2]  Hsin-Yi Lin,et al.  Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis , 2014, BMC Infectious Diseases.

[3]  H. Cox,et al.  32 – Linezolid and Other Oxazolidinones , 2015 .

[4]  G. Patel,et al.  Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study. , 2010, Clinical therapeutics.

[5]  C. Arias,et al.  Enterococcus Species, Streptococcus gallolyticus Group, and Leuconostoc Species , 2015 .

[6]  M. Zervos,et al.  Clinical Outcomes of Daptomycin for Vancomycin-resistant Enterococcus Bacteremia. , 2015, Clinical therapeutics.

[7]  M. Crespo,et al.  Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. , 2003, The Journal of antimicrobial chemotherapy.

[8]  M. Falagas,et al.  Linezolid for the Treatment of Patients with Central Nervous System Infection , 2007, The Annals of pharmacotherapy.

[9]  Piet Claus,et al.  Infective endocarditis: changing epidemiology and predictors of 6-month mortality: a prospective cohort study. , 2006, European heart journal.

[10]  M. Steed,et al.  Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  Michael Barras,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists. , 2010, The Clinical biochemist. Reviews.

[12]  Yen-Hung Lin,et al.  High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. , 2006, International journal of antimicrobial agents.

[13]  S. Miyakis,et al.  Systematic Review and Meta-Analysis of Linezolid versus Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bacteremia , 2013, Antimicrobial Agents and Chemotherapy.

[14]  H. Bundgaard,et al.  Linezolid as rescue treatment for left-sided infective endocarditis: an observational, retrospective, multicenter study , 2012, European Journal of Clinical Microbiology & Infectious Diseases.

[15]  L. Baddour,et al.  Vancomycin-Resistant Enterococcus faecalis Endocarditis: Linezolid Failure and Strain Characterization of Virulence Factors , 2006, Journal of Clinical Microbiology.

[16]  P. Cardona,et al.  Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum , 1996, Antimicrobial agents and chemotherapy.

[17]  E. López García,et al.  [Enterococcal endocarditis]. , 1957, Revista clinica espanola.

[18]  W. G. Maccallum,et al.  A CASE OF ACUTE ENDOCARDITIS CAUSED BY MICROCOCCUS ZYMOGENES (NOV. SPEC.), WITH A DESCRIPTION OF THE MICROORGANISM , 1899, The Journal of experimental medicine.

[19]  M. Zervos,et al.  Endocarditis Caused by Resistant Enterococcus: An Overview , 2013, Current Infectious Disease Reports.

[20]  Ian E. Alexander,et al.  Fibroblasts Can Be Genetically Modified to Produce Excitable Cells Capable of Electrical Coupling , 2005, Circulation.

[21]  Y. Chuang,et al.  Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. , 2010, Diagnostic microbiology and infectious disease.

[22]  L. Friedrich,et al.  Daptomycin in the treatment of bacteremia. , 2007, The American journal of medicine.

[23]  L. Friedrich,et al.  Daptomycin for the treatment of enterococcal bacteraemia: results from the Cubicin Outcomes Registry and Experience (CORE). , 2009, International journal of antimicrobial agents.

[24]  D. Maki,et al.  Enterococcal Bacteremia: Clinical Features, the Risk of Endocarditis, and Management , 1988, Medicine.

[25]  K. Gould,et al.  Clinical update on linezolid in the treatment of Gram-positive bacterial infections , 2012, Infection and drug resistance.

[26]  Á. Soriano,et al.  Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[27]  R. Moellering Emergence of Enterococcus as a significant pathogen. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  P. Linden Optimizing therapy for vancomycin-resistant enterococci (VRE). , 2007, Seminars in respiratory and critical care medicine.

[29]  C. Urban,et al.  Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  H. Derendorf,et al.  Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin , 2010, European journal of medical research.

[31]  Jerome J. Schentag,et al.  Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  G. Bearman,et al.  Central nervous system infections due to vancomycin-resistant enterococci: case series and review of the literature. , 2014, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[33]  M. S. Lee,et al.  Linezolid-associated toxic optic neuropathy. , 2006, Neurology.

[34]  Vance G Fowler,et al.  Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. , 2006, The New England journal of medicine.

[35]  J. Ariza,et al.  Pilot Study of Ampicillin-Ceftriaxone Combination for Treatment of Orthopedic Infections Due to Enterococcus faecalis , 2009, Antimicrobial Agents and Chemotherapy.

[36]  M. Dowzicky Susceptibility to tigecycline and linezolid among gram-positive isolates collected in the United States as part of the tigecycline evaluation and surveillance trial (TEST) between 2004 and 2009. , 2011, Clinical therapeutics.

[37]  V. Cattoir,et al.  Genomic Analysis of Reduced Susceptibility to Tigecycline in Enterococcus faecium , 2014, Antimicrobial Agents and Chemotherapy.

[38]  R. Arbeit,et al.  The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  H. Derendorf,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Tigecycline , 2009, Clinical pharmacokinetics.

[40]  R. Sodian,et al.  Daptomycin: a novel lipopeptide antibiotic against Gram-positive pathogens , 2010, Infection and drug resistance.

[41]  Ronald N. Jones,et al.  Linezolid Surveillance Results for the United States: LEADER Surveillance Program 2011 , 2012, Antimicrobial Agents and Chemotherapy.

[42]  L. Friedrich,et al.  Clinical experience with daptomycin for the treatment of patients with osteomyelitis. , 2007, The American journal of medicine.

[43]  Arjun Srinivasan,et al.  Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009–2010 , 2013, Infection Control & Hospital Epidemiology.

[44]  M. Rybak,et al.  Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model. , 2000, The Journal of antimicrobial chemotherapy.

[45]  C. Finch,et al.  Vancomycin-resistant Enterococcus bacteremia: an evaluation of treatment with linezolid or daptomycin. , 2012, Journal of hospital medicine.

[46]  M. Zervos,et al.  Clinical manifestations of enterococcal infection , 1990, European Journal of Clinical Microbiology and Infectious Diseases.

[47]  G. Noskin,et al.  Postoperative vancomycin-resistant Enterococcus faecium endophthalmitis. , 2007, Archives of ophthalmology.

[48]  J. Bennett,et al.  MANDELL, DAUGLAS AND BENNETT'S PRINCIPLES AND PRACTICE OF INFECTIOUS DISEASE , 2012 .

[49]  K. Rolston,et al.  Daptomycin use in neutropenic patients with documented gram-positive infections , 2013, Supportive Care in Cancer.

[50]  M. Zervos,et al.  High-level resistance to gentamicin in Streptococcus faecalis: risk factors and evidence for exogenous acquisition of infection. , 1986, The Journal of infectious diseases.

[51]  C. Arias,et al.  Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[52]  M. Schintler,et al.  Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. , 2010, The Journal of antimicrobial chemotherapy.

[53]  L. Miller,et al.  Systematic Review and Meta-Analysis of Linezolid and Daptomycin for Treatment of Vancomycin-Resistant Enterococcal Bloodstream Infections , 2013, Antimicrobial Agents and Chemotherapy.

[54]  J. Yombi,et al.  TIGECYCLINE-INDUCED ACUTE PANCREATITIS: ABOUT TWO CASES AND REVIEW OF THE LITERATURE , 2012, Acta clinica Belgica.

[55]  J. Le,et al.  Treatment of Meningitis Caused by Vancomycin-Resistant Enterococcus faecium: High-Dose and Combination Daptomycin Therapy , 2010, The Annals of pharmacotherapy.

[56]  M. Gilmore,et al.  Enterococcal Infection—Treatment and Antibiotic Resistance -- Enterococci: From Commensals to Leading Causes of Drug Resistant Infection , 2014 .

[57]  Ronald N. Jones,et al.  Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: summary of 8 years of a Worldwide Surveillance Programme (2005-2012). , 2014, International journal of antimicrobial agents.

[58]  S. Zimmer,et al.  Peripheral neuropathy associated with prolonged use of linezolid. , 2004, The Lancet. Infectious diseases.

[59]  M. Rybak,et al.  β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. , 2015, The Journal of antimicrobial chemotherapy.

[60]  D. Levine,et al.  Vancomycin: a history. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  C. Arias,et al.  Glycopeptides (Vancomycin and Teicoplanin), Streptogramins (Quinupristin-Dalfopristin), Lipopeptides (Daptomycin), and Lipoglycopeptides (Telavancin) , 2015 .

[62]  C. Cabellos,et al.  Enterococcal Meningitis: A Clinical Study of 39 Cases and Review of the Literature , 2003, Medicine.

[63]  A. MacGowan,et al.  Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. , 2003, The Journal of antimicrobial chemotherapy.

[64]  M. Maley,et al.  Glycopeptide use is associated with increased mortality in Enterococcus faecalis bacteraemia. , 2014, The Journal of antimicrobial chemotherapy.

[65]  J. De La Torre,et al.  Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating enterococcus faecalis infective endocarditis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[66]  G. Martinelli,et al.  Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  Allan R Tunkel,et al.  Practice guidelines for the management of bacterial meningitis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[68]  Brian T. Tsuji,et al.  Ampicillin Enhances Daptomycin- and Cationic Host Defense Peptide-Mediated Killing of Ampicillin- and Vancomycin-Resistant Enterococcus faecium , 2011, Antimicrobial Agents and Chemotherapy.

[69]  You-ning Liu,et al.  Systematic Review and Meta-Analysis of the Effectiveness and Safety of Tigecycline for Treatment of Infectious Disease , 2010, Antimicrobial Agents and Chemotherapy.

[70]  C. Hamilton,et al.  Efficacy and safety of linezolid for Gram-positive orthopedic infections: a prospective case series. , 2007, Diagnostic microbiology and infectious disease.

[71]  D. Herr,et al.  Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  Brian T. Tsuji,et al.  Linezolid‐Associated Peripheral and Optic Neuropathy, Lactic Acidosis, and Serotonin Syndrome , 2007, Pharmacotherapy.

[73]  C. Arias,et al.  Transferable Plasmid-Mediated Resistance to Linezolid Due to cfr in a Human Clinical Isolate of Enterococcus faecalis , 2012, Antimicrobial Agents and Chemotherapy.

[74]  Carmen Torres,et al.  Brief Communication: Treatment of Enterococcus faecalis Endocarditis with Ampicillin plus Ceftriaxone , 2007, Annals of Internal Medicine.

[75]  V. Mave,et al.  Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? , 2007, The Journal of antimicrobial chemotherapy.

[76]  S. Grim,et al.  Safety of linezolid in patients with baseline thrombocytopenia. , 2008, The Journal of antimicrobial chemotherapy.

[77]  R. Holliman,et al.  HIGH-LEVEL GENTAMICIN RESISTANCE IN STREPTOCOCCUS FAECALIS , 1988, The Lancet.

[78]  C. Arias,et al.  Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci. , 2014, International journal of antimicrobial agents.

[79]  B. Murray The life and times of the Enterococcus , 1990, Clinical Microbiology Reviews.

[80]  R. Willcox Ampicillin (“Penbritin”) in the Treatment of Gonorrhoea* , 1963, The British journal of venereal diseases.

[81]  H. Chambers Penicillins and β-Lactam Inhibitors , 2010 .

[82]  M. Zervos,et al.  Nosocomial infection by gentamicin-resistant Streptococcus faecalis. An epidemiologic study. , 1987, Annals of internal medicine.

[83]  M. Gilmore,et al.  Enterococcus Diversity, Origins in Nature, and Gut Colonization , 2014 .